SLC5A2 and chronic kidney disease: The current study also had demonstrated that SGLT2 inhibitors and GLP-1 receptor agonists not only had strong glucose-lowering effects but also can prevent renal damage and the onset of chronic kidney disease, playing a critical role in DKD progression [32].